• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHANG Haowen, CHAI Yingying, CHEN Hanyu, ZHENG Xiao, HAO Haiping, CHEN Xiaohu. Advances in the mechanism of aspirin resistance[J]. Journal of China Pharmaceutical University, 2014, 45(4): 496-503. DOI: 10.11665/j.issn.1000-5048.20140420
Citation: ZHANG Haowen, CHAI Yingying, CHEN Hanyu, ZHENG Xiao, HAO Haiping, CHEN Xiaohu. Advances in the mechanism of aspirin resistance[J]. Journal of China Pharmaceutical University, 2014, 45(4): 496-503. DOI: 10.11665/j.issn.1000-5048.20140420
shu

Advances in the mechanism of aspirin resistance

More Information
    Graphical Abstract
    • Abstract
  • Aspirin is a widely used anti-platelet drug. However, patients continue to experience atherothromboembolic events despite aspirin therapy, which is known as “aspirin resistance(AR)”. Besides the traditional explanation from COX-1—dependent and COX-1—independent mechanism of aspirin resistance, the mechanism under physiological and pathological conditions related to aspirin resistance has been made further progress recently. This review provides a general overview regarding current knowledge about aspirin resistance from the perspective of the pharmacokinetic and pharmacodynamic mechanism under physiological and pathological conditions, respectively. These advances could guide future research toward aspirin resistance and provides potential strategies to improve aspirin efficacy.
    • FullText(HTML)
    • References (43)
  • [1]
    Baigent C,Blackwell L,Collins R,et al.Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials[J].Lancet,2009,373(9 678):1 849-60.
    [2]
    Hedegaard SS,Hvas AM,Grove EL,et al.Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration[J].Thromb Res,2009,124(1):96-100.
    [3]
    Hovens MMC,Snoep JD,Groeneveld Y,et al.High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with type 2 diabetes[J].J Thromb Haemost,2007,5(7):1 562-1 564.
    [4]
    Krasopoulos G,Brister SJ,Beattie WS,et al.Aspirin “resistance” and risk of cardiovascular morbidity:systematic review and meta-analysis[J].Bmj,2008,336( 7637):195-198.
    [5]
    Bliden KP,Tantry US,DiChiara J,et al.Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes[J].Circ Cardiovasc Interv,2011,4(2):118-120.
    [6]
    Lemkes BA,Bähler L,Kamphuisen PW,et al.The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus[J].J Thromb Haemost,2012,10(4):639-646.
    [7]
    Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation[J].J Am Coll Cardiol,2005,46(9):1 705-1 709.
    [8]
    Floyd CN,Ferro A.Mechanisms of aspirin resistance[J].Pharmacol Ther,2014,141(1):69-78.
    [9]
    Grosser T,Fries S,Lawson JA,et al.Drug resistance and pseudoresistance an unintended consequence of enteric coating aspirin[J].Circulation,2013,127(3):377-385.
    [10]
    Hankey GJ,Eikelboom JW.Aspirin resistance[J].Lancet,2006,367(9 510):606-617.
    [11]
    Rocca B,Petrucci G.Variability in the responsiveness to low-dose aspirin:pharmacological and disease-related mechanisms[J].Thrombosis,2012.doi: 10.1155/2012/376721.
    [12]
    Anger K,Kempfert J,Kostelka M,et al.Platelet hyporesponsiveness to acetylsalicylic acid can be transferred by plasma in humans[J].Pharmacology,2010,85(4):241-247.
    [13]
    Kotani K,Kimura S,Ebara T,et al.Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects:different association patterns in subjects with type 2 diabetes mellitus[J].Diabetol Metab Syndr,2010,2(1):50.
    [14]
    König J.Uptake transporters of the human OATP family:molecular characteristics,substrates,their role in drug-drug interactions,and functional consequences of polymorphisms[J].Handb Exp Pharmacol,2011:1-28.
    [15]
    Russel FGM,Koenderink JB,Masereeuw R.Multidrug resistance protein 4(MRP4/ABCC4):a versatile efflux transporter for drugs and signalling molecules[J].Trends Pharmacol Sci,2008,29(4):200-207.
    [16]
    Mattiello T,Guerriero R,Lotti LV,et al.Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport evidence of a reduced drug action in patients after coronary artery bypass grafting[J].J Am Coll Cardiol,2011,58(7):752-761.
    [17]
    Würtz M,Grove EL,Kristensen SD,et al.The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease[J].Heart,2010,96(5):368-371.
    [18]
    Andersson T,Morrison D,Nagy P,et al.Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers[J].Am J Cardiovasc Drugs,2012,12(4):217-224.
    [19]
    Kunicki TJ,Nugent DJ.The genetics of normal platelet reactivity[J].Blood,2010,116(15):2 627-2 634.
    [20]
    Papp E,Havasi V,Bene J,et al.Glycoprotein IIIA gene(PIA)polymorphism and aspirin resistance:is there any correlation[J]?Ann Pharmacother,2005,39(6):1 013-1 018.
    [21]
    Yerges-Armstrong M, Ellero-Simatos S, Georgiades A, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy:pharmacometabolomics-informed pharmacogenomics[J].Clin Pharmacol Ther,2013,94(4):525-532.
    [22]
    Grove EL,Hvas AM,Mortensen SB,et al.Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease[J].J Thromb Haemost,2011,9(1):185-191.
    [23]
    Capodanno D,Patel A,Dharmashankar K,et al.Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease[J].Circ Cardiovasc Interv,2011,4(2):180-187.
    [24]
    Pascale S,Petrucci G,Dragani A,et al.Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target[J].Blood,2012,119(15):3 595-3 603.
    [25]
    Weyrich AS,Schwertz H,Kraiss LW,et al.Protein syntion by aspirin[J].Thromb Res,2000,99(5):487-494.
    [26]
    Ertugrul DT,Tutal E,Yıldız M,et al.Aspirin resistance is associated with glycemic control,the dose of aspirin,and obesity in type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2010,95(6):2 897-2 901.
    [27]
    Watala C,Pluta J,Golanski J,et al.Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood pl?telets to aspirin[J].J Mol Med(Berl),2005,83(2):148-158.
    [28]
    Watala C,Ulicna O,Golanski J,et al.High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats:a multiparametric aggregation study[J].Blood Coagul Fibrinolysis,2006,17(2):113-124.
    [29]
    Riondino S,Trifirò E,Principessa L,et al.Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production[J].,2008,122(3):359-365.
    [30]
    Russo I,Viretto M,Barale C,et al.High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets[J].Diabetes,2012,61(11):2 913-2 921.
    [31]
    Ozben B,Tanrikulu AM,Ozben T,et al.Aspirin resistance in hypertensive patients[J].J Clin Hypertens(Greenwich),2010,12(9):714-720.
    [32]
    Ames PRJ,Batuca JR,Muncy IJ,et al.Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus[J].Thromb Res,2012,130(3):350-354.
    [33]
    Liani R,Halvorsen B,Sestili S,et al.Plasma levels of soluble CD36,platelet activation,inflammation,and oxidative stress are increased in type 2 diabetic patients[J].Free Radic Biol Med,2012,52(8):1 318-1 324.
    [34]
    Bordeaux BC,Qayyum R,Yanek LR,et al.Effect of obesity on platelet reactivity and response to low-dose aspirin[J].Prev Cardiol,2010,13(2):56-62.
    [35]
    Tanrikulu AM, Ozben B, Koc M, et al. Aspirin resistance in patients with chronic renal failure[J].J Nephrol,2011,24(5):636-46.
    [36]
    Blann AD, Kuzniatsova N, Velu S, et al. Renal function and aspirin resistance in patients with coronary artery disease[J].Thromb Res,2012,130(3):e103-e106.
    [37]
    Akoglu H,Agbaht K,Piskinpasa S,et al.High frequency of aspirin resistance in patients with nephrotic syndrome[J].Nephrol Dial Transplant,2012,27(4):1 460-1 466.iated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease:effects of aspirin treatment[J].Am Heart J,2005,149(5):832-839.
    [38]
    McAdam BF,Byrne D,Morrow JD,et al.Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers[J].Circulation,2005,112(7):1 024-1 029.
    [39]
    Bernoud-Hubac N,Alam DA,Lefils J,et al.Low concentrations of reactive γ-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation[J].Biochim Biophys Acta,2009,1 791(4):307-313.
    [40]
    Larsen SB,Grove EL,Kristensen SD,et al.Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease[J].Thromb Haemost,2013,109(5):920-929.
    [41]
    Scirica BM,Morrow DA,Cannon CP,et al.Clinical application of C-reactive protein across the spectrum of acute coronary syndromes[J].Clin Chem,2007,53(10):1 800-1 807.
    [42]
    Missiou A,Wolf D,Platzer I,et al.CD40L induces inflammation and adipogenesis in adipose cells-a potential link between metabolic and cardiovascular disease[J].Thromb Haemost,2010,103(4):788.
    [43]
    Hurlen M,Seljeflot I,Arnesen H.Increased platelet aggregability during exercise in patients with previous myocardial infarction.Lack of inhibit
    • Related Articles

  • Related Articles

    [1]LI Long, GUO Wei, YU Xiuli, XIE Chunwen. Determination of the related substances in desloratadine by HPLC[J]. Journal of China Pharmaceutical University, 2019, 50(6): 707-712. DOI: 10.11665/j.issn.1000-5048.20190611
    [2]XUE Xiaonan, ZHANG Zhengjin, ZOU Qiang, YAN Chao. Determination of dabigatran etexilate mesylate and related substances by HPLC[J]. Journal of China Pharmaceutical University, 2017, 48(6): 711-714. DOI: 10.11665/j.issn.1000-5048.20170612
    [3]LUO Yan, GU Jinhua, LUO Zhiteng, WU Jie, YE Lianbao. Synthesis of the related substances of deferasirox[J]. Journal of China Pharmaceutical University, 2016, 47(3): 288-290. DOI: 10.11665/j.issn.1000-5048.20160306
    [4]ZHANG Changqing, FAN Rong, WANG Feng. Synthesis of two related substances of everolimus[J]. Journal of China Pharmaceutical University, 2015, 46(2): 174-177. DOI: 10.11665/j.issn.1000-5048.20150206
    [5]XU Jie, HU Wenhui, GU Dongfei, HANG Taijun. Identification and determination of related substances in atropine sulfate with hyphenated technique[J]. Journal of China Pharmaceutical University, 2014, 45(4): 438-443. DOI: 10.11665/j.issn.1000-5048.20140410
    [6]ZHAO Xun, YUAN Yaozuo, ZHANG Mei, TAN Li. Determination of pyrazinamide and its related substances by HPLC[J]. Journal of China Pharmaceutical University, 2013, 44(6): 536-539. DOI: 10.11665/j.issn.1000-5048.20130609
    [7]WANG Shang, ZHENG Feng, DING Li. Determination of related substances of vitamin D3 in its preparations by RP-HPLC[J]. Journal of China Pharmaceutical University, 2012, 43(1): 55-59.
    [8]XU Ying, WU Qiong-zhu, KE Xue. Determination of moxifloxacin hydrochloride and its related substances by HPLC[J]. Journal of China Pharmaceutical University, 2012, 43(1): 46-50.
    [9]ZHANG Jin-lin, YUAN Yao-zuo, QIAN Wen, ZHANG Mei. Determination of secnidazole and its related substances by HPLC[J]. Journal of China Pharmaceutical University, 2009, 40(6): 527-530.
    [10]Determination of Ganciclovir and Its Related Substances by HPLC[J]. Journal of China Pharmaceutical University, 2004, (2): 38-40.

  • Cited by

    Periodical cited type(9)

    1. 林丽聪，林煜，钟全福，卓玉琛，樊海平，吴斌，黄美玲. 硫酸新霉素在黑脊倒刺鲃(Spinibarbus caldwelli)体内的残留消除规律研究. 中国渔业质量与标准. 2024(02): 1-6 .
    2. 耿月，朱晓玥，周小华，陈舟舟，朱永强，袁耀佐. 五氟苯基柱HPLC-PAD法测定硫酸巴龙霉素含量及有关物质. 中国药学杂志. 2022(16): 1380-1386 .
    3. 赵敬丹，蒋孟虹，刘浩. 采用HPLC-PED法测定硫酸小诺米星及其注射液有关物质和组分的探讨. 中国抗生素杂志. 2022(10): 1065-1069 .
    4. 赵敬丹，刘浩. 硫酸卡那霉素注射液杂质谱的HPLC-ELSD分析方法的评价与应用. 药物分析杂志. 2021(01): 117-123 .
    5. 程鑫，程华. HPLC-电化学检测法测定美沙拉秦的成分. 质量安全与检验检测. 2021(02): 37-38+50 .
    6. 黄敏文，侯玉荣，张倩，杭太俊，张玫，袁耀佐. 高效液相色谱-脉冲安培电化学检测器法替代微生物检定法测定硫酸新霉素效价的研究. 中国药学杂志. 2020(02): 133-140 .
    7. 黄敏文，张倩，侯玉荣，施海蔚，杭太俊，张玫，袁耀佐. 硫酸新霉素软膏的质量评价. 中国抗生素杂志. 2020(03): 259-266 .
    8. 梁秋霞，刘庄蔚，邓鸣，蒋洁，杨欣智，卢日刚，朱健萍. 曲咪新乳膏质量分析. 中国抗生素杂志. 2020(07): 672-678 .
    9. 李娜，铁益诚，周思茹，毛永强. 快速检测新霉素的荧光传感体系研究. 传感器与微系统. 2020(12): 7-9 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (1144) PDF downloads (2827) Cited by(10)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：299163

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return